Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics.

ABSTRACT:

Background

Extending endocrine therapy from 5 to 10 years is recommended for women with invasive estrogen receptor (ER)-positive breast cancers. We evaluated the benefits and harms of the five additional years of therapy.

Methods

An established Cancer Intervention and Surveillance Network (CISNET) model used a lifetime horizon with national and clinical trial data on treatment efficacy and adverse events and other-cause mortality among multiple birth cohorts of U.S. women ages 25-79 newly diagnosed with ER+, non-metastatic breast cancer. We assumed 100% use of therapy. Outcomes included life years (LYs), quality-adjusted life years (QALYs), and breast cancer mortality. Results were discounted at 3%. Sensitivity analyses tested a 15-year time horizon and alternative assumptio

SUBMITTER: Chandler Y 

PROVIDER: S-EPMC8729060 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature